Prostate cancer patients who seek 2nd opinions often ignore the feedback

Men with prostate cancer often seek out second opinions. But according to new research on men with prostate cancer, this additional step has little to no effect on treatment.

Led by Archana Radhakrishnan, MD, MHS, of Baltimore's Johns Hopkins University, a recent study published online in CANCER from the American Cancer Society analyzed why many men with prostate cancer receive a second opinion but rarely allow it to impact the course of treatment.

The study included 2,386 men with localized prostate cancer between 2012 and 2014. Roughly 40 percent of the men received a second opinion—50.8 percent because they wanted more information about their cancer and 46.3 percent because they wanted to be seen by the best doctor. Subjects said none of the second opinions correlated with receiving definitive treatment or with perceived quality of care.

Results included:

  • Men with second opinions because they were seeking a better urologist were 51 percent less likely to receive definitive treatment.
  • Men who wanted more information were 30 percent less likely to report an excellent quality of care when compared to men without a second opinion.
  • Men who received a second opinion because they were looking for a better doctor, wanted more information and were encouraged by family and friends were most likely to choose surgery as the course of treatment.

"Patients often report getting second opinions for prostate cancer. Their impact on care that patients receive remains uncertain," said Radhakrishnan.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”